Cargando…
PERSEUS 24-month analysis: a prospective non-interventional study to assess the effectiveness of intravitreal aflibercept in routine clinical practice in Germany in patients with neovascular age-related macular degeneration
PURPOSE: To evaluate the real-world effectiveness of intravitreal aflibercept injections in Germany in patients with neovascular age-related macular degeneration over 24 months. METHODS: PERSEUS was a prospective, non-interventional cohort study. The primary endpoint was the mean change in visual ac...
Autores principales: | Eter, Nicole, Hasanbasic, Zoran, Keramas, Georgios, Rech, Christine, Sachs, Helmut, Schilling, Harald, Wachtlin, Joachim, Wiedemann, Peter, Framme, Carsten |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8352822/ https://www.ncbi.nlm.nih.gov/pubmed/33547967 http://dx.doi.org/10.1007/s00417-021-05073-8 |
Ejemplares similares
-
Importance of continuous treatment with intravitreal aflibercept injections in patients with neovascular age-related macular degeneration—12-month post hoc analysis of the PERSEUS real-world evidence study
por: Wachtlin, Joachim, et al.
Publicado: (2020) -
PERSEUS-IT 24-month analysis: a prospective observational study to assess the effectiveness of intravitreal aflibercept in routine clinical practice in Italy in patients with neovascular age-related macular degeneration
por: Nicolò, Massimo, et al.
Publicado: (2022) -
Prospective PED-study of intravitreal aflibercept for refractory vascularized pigment epithelium detachment due to age-related macular degeneration: morphologic characteristics of non-responders in optical coherence tomography
por: Clemens, C. R., et al.
Publicado: (2020) -
Final 4-year results of the RAINBOW real-world study: intravitreal aflibercept dosing regimens in France in treatment-naïve patients with neovascular age-related macular degeneration
por: Cohen, Salomon-Yves, et al.
Publicado: (2022) -
Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration
por: Marquis, Liza-Marie, et al.
Publicado: (2020)